APA (7th ed.) Citation

RT, K., SW, E., R, H., BA, T., MA, S., M, R., . . . PJ, H. (2021). In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). Pediatric blood & cancer, 68(11), e29304. https://doi.org/10.1002/pbc.29304

Chicago Style (17th ed.) Citation

RT, Kurmasheva, Erickson SW, Han R, Teicher BA, Smith MA, Roth M, Gorlick R, and Houghton PJ. "In Vivo Evaluation of the Lysine-specific Demethylase (KDM1A/LSD1) Inhibitor SP-2577 (Seclidemstat) Against Pediatric Sarcoma Preclinical Models: A Report from the Pediatric Preclinical Testing Consortium (PPTC)." Pediatric Blood & Cancer 68, no. 11 (2021): e29304. https://doi.org/10.1002/pbc.29304.

MLA (9th ed.) Citation

RT, Kurmasheva, et al. "In Vivo Evaluation of the Lysine-specific Demethylase (KDM1A/LSD1) Inhibitor SP-2577 (Seclidemstat) Against Pediatric Sarcoma Preclinical Models: A Report from the Pediatric Preclinical Testing Consortium (PPTC)." Pediatric Blood & Cancer, vol. 68, no. 11, 2021, p. e29304, https://doi.org/10.1002/pbc.29304.